TR201903209T4 - Yeniden yapılandırılan yüksek yoğunluğa sahip bir lipoprotein formülasyonu ve bunun üretim yöntemi. - Google Patents
Yeniden yapılandırılan yüksek yoğunluğa sahip bir lipoprotein formülasyonu ve bunun üretim yöntemi. Download PDFInfo
- Publication number
- TR201903209T4 TR201903209T4 TR2019/03209T TR201903209T TR201903209T4 TR 201903209 T4 TR201903209 T4 TR 201903209T4 TR 2019/03209 T TR2019/03209 T TR 2019/03209T TR 201903209 T TR201903209 T TR 201903209T TR 201903209 T4 TR201903209 T4 TR 201903209T4
- Authority
- TR
- Turkey
- Prior art keywords
- high density
- lipid
- density lipoprotein
- formulation
- production method
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 102000015779 HDL Lipoproteins Human genes 0.000 title abstract 2
- 108010010234 HDL Lipoproteins Proteins 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000002632 lipids Chemical class 0.000 abstract 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 2
- 102000007592 Apolipoproteins Human genes 0.000 abstract 2
- 108010071619 Apolipoproteins Proteins 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 206010020961 Hypocholesterolaemia Diseases 0.000 abstract 1
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 231100000304 hepatotoxicity Toxicity 0.000 abstract 1
- 230000007056 liver toxicity Effects 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
- 239000002516 radical scavenger Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Nispeten daha düşük toksisitesi bulunan yeniden yapılandırılan yüksek yoğunluğa sahip bir lipoprotein formülasyonu, ApoAI veya bunun parçası gibi bir apolipoprotein, bir lipid veya bir insana uygulandığında normalde karaciğer toksisitesine neden olan miktarının yaklaşık %5-50?si olan bir seviyede bir temizleyici içerir. Lipid, yaklaşık 30-50g/L şeklinde optimal olarak fosfatidilkolindir ve apolipoprotein:lipidin molar oranı, optimal olarak 1:40 ila 1:75 aralığındadır. Formülasyon, kardiyovasküler hastalık, akut koroner sendroma (ACS) dahil hiperkolesterolemi ve hipokolesterolemi, ateroskleroz ve miyokard enfarktüsü gibi hastalıkların veya durumların tedavi edilmesine yönelik kullanışlıdır.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35992510P | 2010-06-30 | 2010-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201903209T4 true TR201903209T4 (tr) | 2019-03-21 |
Family
ID=45401226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/03209T TR201903209T4 (tr) | 2010-06-30 | 2011-06-30 | Yeniden yapılandırılan yüksek yoğunluğa sahip bir lipoprotein formülasyonu ve bunun üretim yöntemi. |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US8999920B2 (tr) |
| EP (3) | EP3178481B1 (tr) |
| JP (2) | JP5989641B2 (tr) |
| KR (1) | KR101782309B1 (tr) |
| CN (2) | CN103118683B (tr) |
| AU (1) | AU2011274238B2 (tr) |
| CA (1) | CA2803031C (tr) |
| DK (2) | DK3178481T3 (tr) |
| ES (2) | ES2617977T3 (tr) |
| HU (2) | HUE042391T2 (tr) |
| IL (1) | IL223815A (tr) |
| MX (1) | MX2012014928A (tr) |
| PL (2) | PL2588113T3 (tr) |
| SG (1) | SG186386A1 (tr) |
| TR (1) | TR201903209T4 (tr) |
| TW (1) | TWI531388B (tr) |
| WO (1) | WO2012000048A1 (tr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2617977T3 (es) * | 2010-06-30 | 2017-06-20 | Csl Limited | Una formulación de lipoproteína de alta densidad reconstituida y método de producción de la misma |
| US9125943B2 (en) | 2012-11-02 | 2015-09-08 | Csl Limited | Reconstituted HDL formulation |
| CN103833840A (zh) * | 2012-11-27 | 2014-06-04 | 上海复星医药（集团）股份有限公司 | 一种从人血浆中提取高密度脂蛋白及分离纯化载脂蛋白apoA-I的方法 |
| HK1220210A1 (zh) * | 2013-06-05 | 2017-04-28 | Csl Limited | 制备载脂蛋白a-i (apo a-i)的方法 |
| NZ631126A (en) | 2013-08-08 | 2018-06-29 | Csl Ltd | Contaminant removal method |
| EP2853259A1 (en) | 2013-09-30 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Reconstituted high density lipoproteins composition and uses thereof |
| KR101563403B1 (ko) * | 2013-11-05 | 2015-10-26 | 영남대학교 산학협력단 | 지방물질의 안전성 평가방법 |
| CA2947127A1 (en) | 2014-05-02 | 2015-11-19 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
| JP6818264B2 (ja) * | 2014-12-25 | 2021-01-20 | 国立大学法人京都大学 | 高密度リポタンパク質およびその細胞親和性ペプチドを融合した高密度リポタンパク質の点眼による後眼部薬物デリバリー |
| EP3490579B1 (en) | 2016-07-27 | 2025-09-10 | Hartis-Pharma SA | Therapeutic combinations to treat red blood cell disorders |
| US20200038481A1 (en) * | 2016-11-10 | 2020-02-06 | Csl Limited | Reconstituted high density lipoprotein treatment of myocardial infarction |
| JP2021501793A (ja) * | 2017-11-07 | 2021-01-21 | アルファコア ファーマ リミテッド ライアビリティ カンパニーＡｌｐｈａｃｏｒｅ Ｐｈａｒｍａ Ｌｌｃ | 心疾患、心血管疾患及び関連する病状と症状を治療し保護する方法 |
| AU2018396009A1 (en) * | 2017-12-28 | 2020-07-16 | Hdl Therapeutics, Inc. | Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma |
| CN112546201A (zh) * | 2019-09-26 | 2021-03-26 | 中国科学院生物物理研究所 | 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用 |
| KR102531293B1 (ko) * | 2021-12-06 | 2023-05-16 | (주) 멥스젠 | 신규한 재구축 고밀도 지단백 나노입자 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1335077C (en) | 1988-02-08 | 1995-04-04 | Henri Isliker | Process for the manufacture of apolipoproteins from human blood plasma or serum |
| US5652339A (en) | 1993-12-31 | 1997-07-29 | Rotkreuzstiftung Zentrallaboratorium | Method of producing reconstituted lipoproteins |
| PL372925A1 (en) | 2001-09-28 | 2005-08-08 | Esperion Therapeutics Inc. | Prevention and treatment of restenosis by local administration of drug |
| BR0310100A (pt) | 2002-05-17 | 2007-04-27 | Esperion Therapeutics Inc | métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto |
| JP2006507223A (ja) | 2002-05-17 | 2006-03-02 | エスペリオン セラピューティクス，インコーポレイテッド | 脂質代謝異常疾患の治療方法 |
| PE20050438A1 (es) | 2003-10-20 | 2005-06-14 | Esperion Therapeutics Inc | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos |
| US20070254832A1 (en) | 2006-02-17 | 2007-11-01 | Pressler Milton L | Methods for the treatment of macular degeneration and related eye conditions |
| CN100586958C (zh) * | 2006-12-20 | 2010-02-03 | 上海莱士血液制品股份有限公司 | 高纯度载脂蛋白a-i的制备方法 |
| KR100992488B1 (ko) | 2006-12-29 | 2010-11-05 | 주식회사 녹십자 | ＡｐｏＡ-Ｉ의 정제방법 및 정제된ＡｐｏＡ-Ｉ을 이용한재구축 ＨＤＬ의 생산 방법 |
| CA2694854C (en) | 2007-08-17 | 2016-09-27 | Csl Behring Gmbh | Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i |
| US8734853B2 (en) * | 2008-11-17 | 2014-05-27 | University Of North Texas Health Science Center At Fort Worth | HDL particles for delivery of nucleic acids |
| ES2617977T3 (es) | 2010-06-30 | 2017-06-20 | Csl Limited | Una formulación de lipoproteína de alta densidad reconstituida y método de producción de la misma |
| HUE042314T2 (hu) | 2011-02-07 | 2019-06-28 | Cerenis Therapeutics Holding Sa | Lipoprotein komplexek és azok gyártása és alkalmazásai |
| US9125943B2 (en) | 2012-11-02 | 2015-09-08 | Csl Limited | Reconstituted HDL formulation |
-
2011
- 2011-06-30 ES ES11799979.7T patent/ES2617977T3/es active Active
- 2011-06-30 SG SG2012093076A patent/SG186386A1/en unknown
- 2011-06-30 PL PL11799979T patent/PL2588113T3/pl unknown
- 2011-06-30 US US13/805,488 patent/US8999920B2/en active Active
- 2011-06-30 JP JP2013516907A patent/JP5989641B2/ja active Active
- 2011-06-30 CA CA2803031A patent/CA2803031C/en active Active
- 2011-06-30 TW TW100123185A patent/TWI531388B/zh active
- 2011-06-30 CN CN201180036314.1A patent/CN103118683B/zh active Active
- 2011-06-30 HU HUE16203579A patent/HUE042391T2/hu unknown
- 2011-06-30 AU AU2011274238A patent/AU2011274238B2/en active Active
- 2011-06-30 PL PL16203579T patent/PL3178481T3/pl unknown
- 2011-06-30 TR TR2019/03209T patent/TR201903209T4/tr unknown
- 2011-06-30 DK DK16203579.4T patent/DK3178481T3/en active
- 2011-06-30 EP EP16203579.4A patent/EP3178481B1/en active Active
- 2011-06-30 WO PCT/AU2011/000819 patent/WO2012000048A1/en not_active Ceased
- 2011-06-30 ES ES16203579T patent/ES2718234T3/es active Active
- 2011-06-30 DK DK11799979.7T patent/DK2588113T3/en active
- 2011-06-30 EP EP18215066.4A patent/EP3492085A1/en not_active Withdrawn
- 2011-06-30 CN CN201510593566.4A patent/CN105396122B/zh active Active
- 2011-06-30 MX MX2012014928A patent/MX2012014928A/es active IP Right Grant
- 2011-06-30 EP EP11799979.7A patent/EP2588113B1/en active Active
- 2011-06-30 KR KR1020137002377A patent/KR101782309B1/ko active Active
- 2011-06-30 HU HUE11799979A patent/HUE032560T2/en unknown
-
2012
- 2012-12-23 IL IL223815A patent/IL223815A/en active IP Right Grant
-
2015
- 2015-02-27 US US14/633,880 patent/US9439946B2/en active Active
-
2016
- 2016-06-02 JP JP2016110551A patent/JP2016188226A/ja active Pending
- 2016-08-19 US US15/241,895 patent/US10335457B2/en active Active
-
2019
- 2019-06-19 US US16/445,937 patent/US11058747B2/en active Active
-
2021
- 2021-07-06 US US17/368,464 patent/US11723953B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201903209T4 (tr) | Yeniden yapılandırılan yüksek yoğunluğa sahip bir lipoprotein formülasyonu ve bunun üretim yöntemi. | |
| CY1116260T1 (el) | Μεθοδοι παρασκευης παραγωγων κιναζολινονης | |
| EA201200939A1 (ru) | Липиды, липидные композиции и способы их применения | |
| WO2013022922A3 (en) | Fibrous structures | |
| EA201190306A1 (ru) | Улучшенная липидная композиция | |
| EA201500650A1 (ru) | Фенилацетат l-орнитина и способы его получения | |
| MX2010009238A (es) | Estructuras fibrosas grabadas. | |
| EA200700924A1 (ru) | Соединения ряда дибензиламина и их производные | |
| TW200736235A (en) | Dibenzyl amine compounds and derivatives | |
| GB2492674A (en) | Fibrous structures | |
| EA201190099A1 (ru) | (1-фенил-2-пиридин-4-ил)этиловые эфиры бензойной кислоты в качестве ингибиторов фосфодиэстеразы | |
| EP4556073A3 (en) | Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal myocardial infarction in a subject on statin therapy | |
| UA108835C2 (uk) | Спосіб отримання суміші похідних лактиду | |
| BR112015015609A2 (pt) | preparação de ésteres de poli alfa-1,3-glucano e seus filmes | |
| BR112012018384A2 (pt) | composição farmacêutica sólida com intensificadores e métodos de preparação da mesma. | |
| MY192981A (en) | Cyclosporine analogue molecules modified at amino acid 1 and 3 | |
| ATE538100T1 (de) | Aminotetrahydroindazoloessigsäuren | |
| BRPI0408631A (pt) | composição protéica em pó | |
| EA201070477A1 (ru) | Транс-кломифен для лечения метаболического синдрома | |
| RU2009138047A (ru) | Стабилизация витамина в12 | |
| MX344066B (es) | Estructuras fibrosas. | |
| EA200970377A1 (ru) | Композиции фенилалкиламинокарбамата | |
| WO2012119781A3 (en) | Novel lipids, phospholipids, phospholipid and lipid compositions and their use | |
| PH12013500893A1 (en) | Methods of treatment using lipid compounds | |
| NZ631131A (en) | Reconstituted hdl formulation |